Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veverimer in Chronic Kidney Disease with Metabolic Acidosis
NCT03710291Phase 3Terminated
- Sponsor
- Tricida, Inc.
- Start
- Nov 2018
- Primary completion
- Aug 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of veverimer in chronic kidney disease (CKD), metabolic acidosis, sponsored by Tricida, Inc.. Started Nov 2018; status: terminated.
02
Drugs
veverimer
03
Conditions
chronic kidney disease (CKD)metabolic acidosis
Beyond the preview
Go deeper on NCT03710291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710291.